'Second line medications' for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide
| Autor: | Brady S. Moffett, Christina Y. Miyake, Santiago O. Valdes, Jeffrey J. Kim, Peter C Kahr |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Heart disease Digoxin 030204 cardiovascular system & hematology QT interval 03 medical and health sciences QRS complex 0302 clinical medicine Physiology (medical) Internal medicine medicine Humans cardiovascular diseases 030212 general & internal medicine Adverse effect Child Flecainide business.industry Sotalol Arrhythmias Cardiac medicine.disease Hospitals Discontinuation Cardiology Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Journal of cardiovascular electrophysiologyREFERENCES. 32(8) |
| ISSN: | 1540-8167 |
| Popis: | INTRODUCTION Sotalol and flecainide are used as second line agents in children for the treatment of supraventricular arrhythmias (SA) refractory to anti-beta adrenergic antiarrhythmics or digoxin. Efficacy and adverse events in this cohort have not been well described. Here, we report our institutional experience of second line treatment initiation for SA in children. METHODS AND RESULTS Utilizing an institutional database, 247 patients initiated on sotalol and 81 patients initiated on flecainide were identified. Congenital heart disease (CHD) was present in 40% of patients. Arrhythmia-free discharge on single or dual agent therapy (in combination with other antiarrhythmics) was 87% for sotalol and 91% for flecainide. Neither age, sex, dosing, presence of CHD nor arrhythmia subtype were associated with alterations in in-hospital efficacy. Compared to baseline, QTc intervals in sotalol patients (436 [416-452 ms] vs. 415 [400-431 ms], p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text